期刊文献+

多发性骨髓瘤患者中N-ras基因突变的检测及其意义 被引量:1

Detection of N-ras Gene Mutations in Multiple Myeloma and Its Si gnificance
下载PDF
导出
摘要 目的 了解多发性骨髓瘤 (multiplemyeloma ,MM)患者中N ras基因突变率及临床意义。方法 采用聚合酶链反应 单链构象多态性银染法检测MM患者的N ras基因突变 ,并结合临床分析。结果  14例MM患者中 ,4例在N ras第 6 1密码子 ,1例在第 12、13密码子处发生突变 ,突变率为 35 .7%。突变者中 4例已死亡 ,其中 2例检测突变时已处于疾病终末期。结论 N ras基因在MM中有较高的突变率 ,对其的检测有助于病程进展和预后的分析。 Objective To investigate mutation rate of N-ras in multiple myeloma(MM) and discuss the clinical significance of MM associated with N-ras gene mutations.Methods The N-ras gene mutations in 14 cases of MM were detected by the methods of polymeras chain reaction-single strand conformation polymorphism (PCR-SSCP) and silver staining technique. Both clinical features and laboratory results were analyzed simultaneously.Results There were mutation of N-ras in five cases (35.7%), four in codon 61, and one in codon 12 or 13. Four of them died, and two of them were detected mutations at the terminal stage of the disease.Conclusion It showed that a relative high frequence of N-ras gene mu tation was found in MM. And detecting N-ras gene mutations in MM might be benef it to evaluate the progression and prognosis of disease.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 2000年第5期347-349,共3页 Journal of Nanjing Medical University(Natural Sciences)
关键词 多发性骨髓瘤 多聚酶链反应 N-ras基因突变 oncogene, N-ras multiple Myeloma polymerase chain react ion single-stranded conformation polymorphism
  • 相关文献

参考文献3

共引文献8

同被引文献18

  • 1Chapman MA,Lawrenee MS,Keats JJ,et al. Initial genome se- quencing and analysis of multiple myeloma[J]. Nature, 2011, 471(7339) :467-472.
  • 2Ortega MM,Faria RM, Shitara ES, et al. N-ras and k-ras gene mutations in brazilian patients with multiple myeloma[J]. Leuk Lymphoma, 2006,47 (2) : 285-289.
  • 3Weiss BM, Kuehl WM. Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of mul- tiple myeloma[J]. Expert Rev Hematol,2010,3(2):165-174.
  • 4Intini D, Agneni L, Ciceri G, et al. Relevance of ras gene muta- tions in the context of the molecular heterogeneity of multiplemyeloma[J]. Hematol Oncol,2007,25(1) :6-10.
  • 5Rasmussen T,Kuehl M,Lodahl M,et al. Possible roles for acti- vating ras mutations in the mgus to mm transition and in the in- tramedullary to extramedullary transition in some plasma cell tumors[J]. Blood,2005,105(1) :317-323.
  • 6Chng WJ, Gonzalez-Paz N, Price-Troska T, et al. Clinical and bi- ological significance of ras mutations in multiple myeloma[J]. Leukemia, 2008,22 (12) : 2280-2284.
  • 7Liu P,Leong T,Quam L,et al. Activating mutations of n- and k- ras in multiple myeloma show different clinical associations: A- nalysis of the eastern cooperative oncology group phase iii trial [J]. Blood, 1996,88(7) : 2699-2706.
  • 8Yasuga Y, Hirosawa S,Yamamoto K, et al. N-ras and p53 gene mutations are very rare events in multiple myeloma[J]. Int J Hematol,1995,62(2) :91-97.
  • 9Jaiswal BS,Janakiraman V, Kljavin NM, et al. Combined targe- ting of braf and craf or braf and pi3k effector pathways is re- quired for efficacy in nras mutant tumors[J]. PLoS One,2009,4 (5): e5717.
  • 10Lovly CM,Dahlman KB,Fohn LE,et al. Routine multiplex mu- tational profiling of melanomas enables enrollment in genotype- driven therapeutic trials[J]. PLoS One,2012,7(4) :e35309.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部